S&P 500   3,154.47 (+0.84%)
DOW   27,300.60 (+0.81%)
QQQ   217.95 (+1.20%)
AAPL   289.08 (+0.35%)
FB   199.19 (+1.23%)
MSFT   170.31 (+1.33%)
AMZN   1,985.00 (+0.62%)
CGC   19.74 (+0.61%)
NVDA   265.31 (+1.24%)
BABA   209.36 (+1.82%)
MU   53.15 (+2.02%)
GE   11.29 (-0.35%)
TSLA   785.00 (-1.86%)
AMD   48.23 (+1.39%)
T   37.11 (-0.67%)
ACB   1.50 (-0.66%)
NFLX   368.72 (+2.40%)
PRI   121.42 (+0.00%)
BAC   31.37 (+0.93%)
DIS   126.64 (-1.21%)
GILD   71.54 (+2.05%)
S&P 500   3,154.47 (+0.84%)
DOW   27,300.60 (+0.81%)
QQQ   217.95 (+1.20%)
AAPL   289.08 (+0.35%)
FB   199.19 (+1.23%)
MSFT   170.31 (+1.33%)
AMZN   1,985.00 (+0.62%)
CGC   19.74 (+0.61%)
NVDA   265.31 (+1.24%)
BABA   209.36 (+1.82%)
MU   53.15 (+2.02%)
GE   11.29 (-0.35%)
TSLA   785.00 (-1.86%)
AMD   48.23 (+1.39%)
T   37.11 (-0.67%)
ACB   1.50 (-0.66%)
NFLX   368.72 (+2.40%)
PRI   121.42 (+0.00%)
BAC   31.37 (+0.93%)
DIS   126.64 (-1.21%)
GILD   71.54 (+2.05%)
S&P 500   3,154.47 (+0.84%)
DOW   27,300.60 (+0.81%)
QQQ   217.95 (+1.20%)
AAPL   289.08 (+0.35%)
FB   199.19 (+1.23%)
MSFT   170.31 (+1.33%)
AMZN   1,985.00 (+0.62%)
CGC   19.74 (+0.61%)
NVDA   265.31 (+1.24%)
BABA   209.36 (+1.82%)
MU   53.15 (+2.02%)
GE   11.29 (-0.35%)
TSLA   785.00 (-1.86%)
AMD   48.23 (+1.39%)
T   37.11 (-0.67%)
ACB   1.50 (-0.66%)
NFLX   368.72 (+2.40%)
PRI   121.42 (+0.00%)
BAC   31.37 (+0.93%)
DIS   126.64 (-1.21%)
GILD   71.54 (+2.05%)
S&P 500   3,154.47 (+0.84%)
DOW   27,300.60 (+0.81%)
QQQ   217.95 (+1.20%)
AAPL   289.08 (+0.35%)
FB   199.19 (+1.23%)
MSFT   170.31 (+1.33%)
AMZN   1,985.00 (+0.62%)
CGC   19.74 (+0.61%)
NVDA   265.31 (+1.24%)
BABA   209.36 (+1.82%)
MU   53.15 (+2.02%)
GE   11.29 (-0.35%)
TSLA   785.00 (-1.86%)
AMD   48.23 (+1.39%)
T   37.11 (-0.67%)
ACB   1.50 (-0.66%)
NFLX   368.72 (+2.40%)
PRI   121.42 (+0.00%)
BAC   31.37 (+0.93%)
DIS   126.64 (-1.21%)
GILD   71.54 (+2.05%)
Log in

CytRx News Headlines (OTCMKTS:CYTR)

$0.53
-0.07 (-11.73 %)
(As of 02/26/2020 09:40 AM ET)
Today's Range
$0.52
Now: $0.53
$0.60
50-Day Range
$0.31
MA: $0.48
$0.73
52-Week Range
$0.21
Now: $0.53
$0.85
Volume100,283 shs
Average Volume120,437 shs
Market Capitalization$17.73 million
P/E RatioN/A
Dividend YieldN/A
Beta1.71

Headlines

CytRx (OTCMKTS CYTR) News Headlines

Source:
DateHeadline
Kinase Inhibitors Market Innovative Solutions By Top Key Players Cytrx Corporation, Boehringer Ingelheim, Eton Bioscience Inc., GlaxosmithklineKinase Inhibitors Market Innovative Solutions By Top Key Players Cytrx Corporation, Boehringer Ingelheim, Eton Bioscience Inc., Glaxosmithkline
www.marketwatch.com - February 18 at 5:59 PM
Critical Comparison: CytRx (OTCMKTS:CYTR) vs. Voyager Therapeutics (OTCMKTS:VYGR)Critical Comparison: CytRx (OTCMKTS:CYTR) vs. Voyager Therapeutics (OTCMKTS:VYGR)
www.americanbankingnews.com - February 14 at 2:06 AM
CytRx up 127% on positive arimoclomol data in rare muscle disorder - Seeking AlphaCytRx up 127% on positive arimoclomol data in rare muscle disorder - Seeking Alpha
seekingalpha.com - February 11 at 12:40 PM
CytRx Corporation Highlights Recently Published Data of its Licensee Orphazyme A/S Phase 2 Trial of Arimoclomol in the Treatment of Sporadic Inclusion Body Myositis (sIBM)CytRx Corporation Highlights Recently Published Data of its Licensee Orphazyme A/S Phase 2 Trial of Arimoclomol in the Treatment of Sporadic Inclusion Body Myositis (sIBM)
finance.yahoo.com - February 11 at 12:40 PM
Immix Doses First Patient in USA in its Phase 1b/2a Trial in Patients with Advanced Solid Tumors - Yahoo FinanceImmix Doses First Patient in USA in its Phase 1b/2a Trial in Patients with Advanced Solid Tumors - Yahoo Finance
finance.yahoo.com - February 4 at 2:19 PM
CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Licensee Orphazyme A/S - Yahoo FinanceCytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Licensee Orphazyme A/S - Yahoo Finance
finance.yahoo.com - February 4 at 2:19 PM
Immix Doses First Patient in USA in its Phase 1b/2a Trial in Patients with Advanced Solid Tumors - PRNewswireImmix Doses First Patient in USA in its Phase 1b/2a Trial in Patients with Advanced Solid Tumors - PRNewswire
www.prnewswire.com - February 4 at 9:17 AM
CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Licensee Orphazyme A/S - PRNewswireCytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Licensee Orphazyme A/S - PRNewswire
www.prnewswire.com - February 4 at 9:17 AM
CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Licensee Orphazyme A/SCytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Licensee Orphazyme A/S
finance.yahoo.com - February 4 at 9:17 AM
CytRx Corporation Highlights Significant Positive Events From its Licensed Drug Aldoxorubicin - Yahoo FinanceCytRx Corporation Highlights Significant Positive Events From its Licensed Drug Aldoxorubicin - Yahoo Finance
finance.yahoo.com - January 29 at 12:12 PM
CytRx Corporation Highlights Significant Positive Events From its Licensed Drug AldoxorubicinCytRx Corporation Highlights Significant Positive Events From its Licensed Drug Aldoxorubicin
finance.yahoo.com - January 29 at 12:12 PM
CytRx up 2% on accelerated review tags for arimoclomolCytRx up 2% on accelerated review tags for arimoclomol
seekingalpha.com - December 20 at 8:29 AM
CytRx Corporation Highlights Significant Positive Events From its Two Licensed Drugs Arimoclomol and Aldoxorubicin - Yahoo FinanceCytRx Corporation Highlights Significant Positive Events From its Two Licensed Drugs Arimoclomol and Aldoxorubicin - Yahoo Finance
finance.yahoo.com - December 19 at 5:22 PM
Form 8-K CYTRX CORP For: Dec 13 - StreetInsider.comForm 8-K CYTRX CORP For: Dec 13 - StreetInsider.com
www.streetinsider.com - December 19 at 12:21 PM
CytRx Corporation Highlights Significant Positive Events From its Two Licensed Drugs Arimoclomol and Aldoxorubicin - PRNewswireCytRx Corporation Highlights Significant Positive Events From its Two Licensed Drugs Arimoclomol and Aldoxorubicin - PRNewswire
www.prnewswire.com - December 19 at 12:21 PM
CytRx Corporation Highlights Significant Positive Events From its Two Licensed Drugs Arimoclomol and AldoxorubicinCytRx Corporation Highlights Significant Positive Events From its Two Licensed Drugs Arimoclomol and Aldoxorubicin
finance.yahoo.com - December 19 at 12:21 PM
Strong On High Relative Volume: CytRx (CYTR)Strong On High Relative Volume: CytRx (CYTR)
www.thestreet.com - November 1 at 7:02 PM
Kinase Inhibitors Market Growth Predictions, Leading Players : Cytrx Corporation, Boehringer Ingelheim, Eton Bioscience Inc.Kinase Inhibitors Market Growth Predictions, Leading Players : Cytrx Corporation, Boehringer Ingelheim, Eton Bioscience Inc.
www.marketwatch.com - November 1 at 9:01 AM
CytRx Bear Thesis Explained: Why Sarcoma Drug Trial Will FailCytRx Bear Thesis Explained: Why Sarcoma Drug Trial Will Fail
www.thestreet.com - October 30 at 11:03 PM
Stocks That Hit 52-Week Lows On Monday - BenzingaStocks That Hit 52-Week Lows On Monday - Benzinga
www.benzinga.com - October 14 at 5:38 PM
CytRx CorpCytRx Corp
www.bloomberg.com - October 2 at 8:59 PM
Form 10-Q CYTRX CORP For: Jun 30 - StreetInsider.comForm 10-Q CYTRX CORP For: Jun 30 - StreetInsider.com
www.streetinsider.com - August 9 at 4:52 PM
CytRx Corporation Reports Second Quarter 2019 Financial Results - PRNewswireCytRx Corporation Reports Second Quarter 2019 Financial Results - PRNewswire
www.prnewswire.com - August 9 at 4:52 PM
CytRx Corporation Reports Second Quarter 2019 Financial ResultsCytRx Corporation Reports Second Quarter 2019 Financial Results
finance.yahoo.com - August 9 at 3:17 PM
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in US for Niemann-Pick Disease Type C - PRNewswireCytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in US for Niemann-Pick Disease Type C - PRNewswire
www.prnewswire.com - July 30 at 11:31 AM
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in U.S. for Niemann-Pick Disease Type CCytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in U.S. for Niemann-Pick Disease Type C
finance.yahoo.com - July 30 at 11:31 AM
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment in its Phase 3 Clinical Trial of Arimoclomol in Amyotrophic Lateral Sclerosis - PRNewswireCytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment in its Phase 3 Clinical Trial of Arimoclomol in Amyotrophic Lateral Sclerosis - PRNewswire
www.prnewswire.com - July 23 at 12:44 PM
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment in its Phase 3 Clinical Trial of Arimoclomol in Amyotrophic Lateral Sclerosis - Yahoo FinanceCytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment in its Phase 3 Clinical Trial of Arimoclomol in Amyotrophic Lateral Sclerosis - Yahoo Finance
finance.yahoo.com - July 22 at 11:03 AM
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment in its Phase 3 Clinical Trial of Arimoclomol in Amyotrophic Lateral SclerosisCytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment in its Phase 3 Clinical Trial of Arimoclomol in Amyotrophic Lateral Sclerosis
finance.yahoo.com - July 22 at 11:03 AM
CytRx Corporation Discusses Near Term Value from Out-License Deals and Growth Drivers for 2019 in New SNNLive Video Interview on StockNewsNow.com - Yahoo FinanceCytRx Corporation Discusses Near Term Value from Out-License Deals and Growth Drivers for 2019 in New SNNLive Video Interview on StockNewsNow.com - Yahoo Finance
finance.yahoo.com - June 27 at 10:39 AM
CytRx Corporation Discusses Near Term Value from Out-License Deals and Growth Drivers for 2019 in New SNNLive Video Interview on StockNewsNow.comCytRx Corporation Discusses Near Term Value from Out-License Deals and Growth Drivers for 2019 in New SNNLive Video Interview on StockNewsNow.com
finance.yahoo.com - June 27 at 10:39 AM
Form 8-K CYTRX CORP For: Jun 25 - StreetInsider.comForm 8-K CYTRX CORP For: Jun 25 - StreetInsider.com
www.streetinsider.com - June 26 at 11:01 AM
Form DEF 14A CYTRX CORP For: Jun 26 - StreetInsider.comForm DEF 14A CYTRX CORP For: Jun 26 - StreetInsider.com
www.streetinsider.com - June 26 at 11:01 AM
CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation - PRNewswireCytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation - PRNewswire
www.prnewswire.com - June 26 at 11:01 AM
Delisting of Securities of FTD Companies, Inc., Kaixin Auto Holdings (Warrant Only), CytRx Corporation, and Insys Therapeutics, Inc. from The Nasdaq Stock Market - NasdaqDelisting of Securities of FTD Companies, Inc., Kaixin Auto Holdings (Warrant Only), CytRx Corporation, and Insys Therapeutics, Inc. from The Nasdaq Stock Market - Nasdaq
www.nasdaq.com - June 22 at 11:02 AM
Delisting of Securities of FTD Companies, Inc., Kaixin Auto Holdings (Warrant Only), CytRx Corporation, and Insys Therapeutics, Inc. from The Nasdaq Stock Market - GlobeNewswireDelisting of Securities of FTD Companies, Inc., Kaixin Auto Holdings (Warrant Only), CytRx Corporation, and Insys Therapeutics, Inc. from The Nasdaq Stock Market - GlobeNewswire
globenewswire.com - June 21 at 4:23 PM
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S to Prepare Regulatory Submission in Europe for Niemann-Pick Disease Type C - Yahoo FinanceCytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S to Prepare Regulatory Submission in Europe for Niemann-Pick Disease Type C - Yahoo Finance
finance.yahoo.com - June 19 at 10:10 AM
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S to Prepare Regulatory Submission in Europe for Niemann-Pick Disease Type CCytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S to Prepare Regulatory Submission in Europe for Niemann-Pick Disease Type C
finance.yahoo.com - June 19 at 10:10 AM
CytRx Corporation to Commence Trading on OTCQB Venture Market - Yahoo FinanceCytRx Corporation to Commence Trading on OTCQB Venture Market - Yahoo Finance
finance.yahoo.com - June 1 at 11:22 AM
CytRx Corporation to Commence Trading on OTCQB Venture Market - PRNewswireCytRx Corporation to Commence Trading on OTCQB Venture Market - PRNewswire
www.prnewswire.com - May 31 at 11:11 AM
CytRx beats by $0.02 - Seeking AlphaCytRx beats by $0.02 - Seeking Alpha
seekingalpha.com - May 15 at 11:28 AM
CytRx Corporation Reports First Quarter 2019 Financial Results - Yahoo FinanceCytRx Corporation Reports First Quarter 2019 Financial Results - Yahoo Finance
finance.yahoo.com - May 15 at 11:28 AM
CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer - Yahoo FinanceCytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer - Yahoo Finance
finance.yahoo.com - May 8 at 11:24 AM
CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain CancerCytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer
finance.yahoo.com - May 8 at 11:24 AM
CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S - PRNewswireCytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S - PRNewswire
www.prnewswire.com - May 3 at 4:23 PM
CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S - Yahoo FinanceCytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S - Yahoo Finance
finance.yahoo.com - May 2 at 11:41 AM
CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/SCytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S
finance.yahoo.com - May 2 at 11:41 AM
Recent Analysis Shows Regulus Therapeutics, Limbach, CytRx, and Rand Capital Market Influences — Renewed Outlook, Key Drivers of Growth - GlobeNewswireRecent Analysis Shows Regulus Therapeutics, Limbach, CytRx, and Rand Capital Market Influences — Renewed Outlook, Key Drivers of Growth - GlobeNewswire
www.globenewswire.com - May 1 at 4:07 PM
CytRx (CYTR) Reports Complete Enrollment in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S - StreetInsider.comCytRx (CYTR) Reports Complete Enrollment in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S - StreetInsider.com
www.streetinsider.com - April 29 at 11:09 AM
CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S - Yahoo FinanceCytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S - Yahoo Finance
finance.yahoo.com - April 29 at 11:09 AM
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel